Abemaciclib improved progression-free survival at 6 months in meningiomas with NF2 or CDK pathway alterations, achieving a 58 ...

Patients receiving the tafasitamab combination achieved a median PFS of 22.4 months, compared with 13.9 months for patients receiving placebo with lenalidomide and rituximab. This represents a 57% ...

Investigators compared the efficacy and safety of suvemcitug plus chemotherapy vs chemotherapy plus placebo for patients with platinum-refractory or resistant ovarian cancer.

The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for ...

Investigators assessed whether anticoagulation and platelet aggregation inhibition could have antitumoral effects when used along side targeted therapies for patients with unresectable stage III-IV ...

In younger patients with chronic lymphocytic leukemia (CLL), treatment with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFRC) led to strong progression-free survival (PFS) and durable ...

Multiple long-term follow-up studies confirm BRUKINSA’s superior efficacy and favorable tolerability versus ibrutinib in relapsed or refractory CLL Additional ASH data from investigational BTK ...

Please provide your email address to receive an email when new articles are posted on . Results showed longer median PFS and a higher 9-month PFS with ivonescimab than pembrolizumab. Patients with ...

But is the combination a "viable alternative" to nivolumab and ipilimumab?

Please provide your email address to receive an email when new articles are posted on . Women with advanced ovarian cancer derived significant quality-adjusted PFS benefit from niraparib compared with ...